Oritavancin

Summary

Oritavancin (CHEMBL1688530) is an approved small-molecule antibacterial drug (ATC J01XA05); indicated across 2 conditions including bacterial infectious disease and skin disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01XA05
• Indications: 2 conditions
• Clinical trials: 11
• Chemistry: 1793.1 Da · C86H97Cl3N10O26

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1688530
Name	Oritavancin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	16136912
ChEBI	CHEBI:82699
ATC	J01XA05
Molecular formula	C86H97Cl3N10O26
Molecular weight	1793.1
InChIKey	VHFGEBVPHAGQPI-LXKZPTCJSA-N

SMILES: C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)[C@H](C(=O)N3)NC(=O)[C@H]6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)[C@H]([C@H](C(=O)N[C@H](C(=O)N6)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O

IUPAC name: (1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5R,6S)-4-[[4-(4-chlorophenyl)phenyl]methylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid

ChEBI definition: A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA.

Pharmacological roles (ChEBI): antibacterial drug, antimicrobial agent.

Also known as: LY-333328, LY333328, Oritavancin, Oritavancina, Oritavancine, oritavancin, ORITAVANCIN, ORITAVANCIN (DIPHOSPHATE), Oritavancin (diphosphate)

Parent form; salt/anhydrous children: CHEMBL3989766

Patent coverage: 54 distinct patent families (69 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 54 (78%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
skin disorder	2	MONDO:0005093	EFO:0000701

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE4	4
PHASE1	4
PHASE2	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02452918	PHASE4	COMPLETED	A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
NCT02925416	PHASE4	COMPLETED	Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection
NCT03761953	PHASE4	WITHDRAWN	Oritavancin for Staphylococcus Aureus Infections in Opioid Users
NCT05521880	PHASE4	TERMINATED	Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use
NCT07550595	PHASE2	NOT_YET_RECRUITING	Oritavancin for Treatment of Serious Cardiac Infections
NCT00514527	PHASE2	COMPLETED	A Study for Patients With Complicated Skin and Skin Structure Infections
NCT02134301	PHASE1	COMPLETED	Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections
NCT02357524	PHASE1	COMPLETED	Oritavancin on the Results of Multiple Coagulation Tests in Healthy Volunteers
NCT02470702	PHASE1	COMPLETED	Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects
NCT02471690	PHASE1	COMPLETED	Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers
NCT03159403	Not specified	COMPLETED	A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).